Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-09-18
2009-12-01
Rao, Manjunath N (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C530S388230, C530S389100, C530S350000, C530S300000
Reexamination Certificate
active
07626002
ABSTRACT:
Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
REFERENCES:
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 2002/0062010 (2002-05-01), Carter et al.
patent: 2003/0219433 (2003-11-01), Hansen et al.
patent: 2004/0009150 (2004-01-01), Nelson et al.
patent: 2004/0110932 (2004-06-01), Novak et al.
patent: 2004/0260065 (2004-12-01), Novak et al.
patent: 2005/0265966 (2005-12-01), Kindsvogel et al.
patent: 2006/0134754 (2006-06-01), Zamost et al.
patent: 2006/0269973 (2006-11-01), Yee
patent: 2007/0041940 (2007-02-01), Nelson et al.
patent: 2007/0041974 (2007-02-01), Novak et al.
patent: 2007/0048260 (2007-03-01), Novak et al.
patent: 2007/0048263 (2007-03-01), Meyer
patent: 2007/0048264 (2007-03-01), Kingsvogel et al.
patent: 2007/0048266 (2007-03-01), Nelson et al.
patent: 2007/0048267 (2007-03-01), Nelson et al.
patent: 2007/0048268 (2007-03-01), Nelson et al.
patent: 2007/0048269 (2007-03-01), Nelson et al.
patent: 2007/0048270 (2007-03-01), Nelson et al.
patent: 2007/0048271 (2007-03-01), Nelson et al.
patent: 2007/0048272 (2007-03-01), Nelson et al.
patent: 2007/0048273 (2007-03-01), Nelson et al.
patent: 2007/0048798 (2007-03-01), Zamost et al.
patent: 2007/0048842 (2007-03-01), Zamost et al.
patent: 2007/0048845 (2007-03-01), Novak et al.
patent: 2007/0049529 (2007-03-01), Novak et al.
patent: 2007/0049548 (2007-03-01), Nelson et al.
patent: 2007/0049549 (2007-03-01), Nelson et al.
patent: 2007/0054320 (2007-03-01), Novak et al.
patent: 2007/0059284 (2007-03-01), Nelson et al.
patent: 2007/0059825 (2007-03-01), Novak et al.
patent: 2007/0066807 (2007-03-01), Novak et al.
patent: 2007/0066808 (2007-03-01), Novak et al.
patent: 2007/0086980 (2007-04-01), Nelson et al.
patent: 2007/0092485 (2007-04-01), Novak et al.
patent: 2007/0098682 (2007-05-01), Novak et al.
patent: 2007/0098683 (2007-05-01), Novak et al.
patent: 2007/0099269 (2007-05-01), Novak et al.
patent: 2007/0122382 (2007-05-01), Kindsvogel et al.
patent: 2007/0128161 (2007-06-01), Nelson et al.
patent: 2007/0166794 (2007-07-01), Novak et al.
patent: 2007/0178063 (2007-08-01), Kindsvogel et al.
patent: 03/103589 (2003-12-01), None
patent: 2004/032857 (2004-04-01), None
patent: 2004/056392 (2004-07-01), None
patent: 2005/037306 (2005-04-01), None
Clegg et al., “Therapeutic opportunities for IL-21,”European Cytokine Network14(3):28, 2003.
Nelson et al., “Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2,” Proceedings of the American Association for Cancer Research Annual Meeting 44:562, 2003.
Funaro et al., “Monoclonal antibodies and therapy of human cancers,”Biotechnology Advances18(5):385-401, 2000.
Ozaki et al., “Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6,”Immunol. 173(9):5361-71, 2004.
Aklulu et al., “Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma,”Ann Oncol. 15(7):1109-14, 2004.
Moroz et al., “IL-21 enhances and sustains CD8+ T cell responses to achieve duragble tumor immunity: comparative evaluation of IL-2,IL-15, and IL-21,”J Immunol. 173(2):900-9, 2004.
O'Shea et al., “Jak3 and the pathogenesis of severe combined immunodeficiency,”Mol Immunol. 727-37, 2004.
Sivakumar et al., Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses,:Immunology112(2):177-82, 2004.
Munshi, “Recent advances in the management of multiple myeloma,”Semin Hematol. 2(4):21-6, 2004.
Rowshani et al., “Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro,”Eur J Immunol. 34(3):882-99, 2004.
Sievers et al., “IL-21 enhances trastuzumab-mediated killing of breast cancer cell lines in vitro,”Breast Cancer Res. And Treatment S1(0):6075, 2004.
Kindsvogel et al.., “IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo,”J. Clin. Oncol. 22(14S):2581, 2004.
Hughes et al., “Interleukin 21 efficacy in a mouse model of metastatic renal cell carcinoma,”J. Clin. Oncol, 22(14S)2598, 2004.
Sivakumar et al., “Interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical Trials.,”J. Immunother. 27(6):S56, 2004.
Hughes et al., “Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model,”Blood104(11):394A, 2004.
Rastetter et al., “Rituximab: expanding role in therapy for lymphomas and autoimmune diseases,”Annu Rev Med. 55:477-503, 2004.
Akamatsu et al., “Selected IL-21 R Expression and Apoptosis Induction by IL-21 in Follicular Lymphoma,”Blood104(11 ):629A, 2004.
Ueda et al., “Expression of Functional IL-21 Receptor on adult T-cell Leukemia Cells,”Blood102(11), 2003.
Gitlitz et al., “Cytokine-based therapy for metastatic renal cell cancer,”Urol Clin North Am. (3):589-600, 2003.
Ma et al., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamms,J. Immunol. 171(2):608-15, 2003.
Mehta et al., “IL-21 induces the apoptosis of resting and activated primary B cells,”J Immunol.. 170(8):4111-8, 2003.
Strengell et al., “IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response,”J Immunol. 169(7):3600-5, 2002.
Nelson et al., “Anti-tumor Effects of Interleukin 21,” Immunobiology of Lymphomna abstr. 593, 2002.
Parrish-Novak et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature408(6808):57-63, 2000.
Ro et al., “IL-21 is a Growth and Survival Factor for Human Myeloma Cells,”Blood98(1 I):abst. 3216, 2001.
U.S. Appl. No. 11/533,367, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,395, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/346,580, filed Feb. 2, 2006, Novak et al.
Dillon Stacey R.
Foster Donald C.
Gross Jane A.
Hammond Angela K.
Holly Richard D.
Lewis Michelle L.
Rao Manjunath N
Sawislak Deborah A.
Wegert Sandra
ZymoGenetics Inc.
LandOfFree
Cytokine zalpha11 ligand antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine zalpha11 ligand antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine zalpha11 ligand antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065138